Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Treatment of Chronic Hepatitis C in Special Populations
Authors: Chalermrat Bunchorntavakul
Tawesak Tanwandee
Rangsit University
Mahidol University
Keywords: Medicine
Issue Date: 1-Dec-2015
Citation: Gastroenterology Clinics of North America. Vol.44, No.4 (2015), 883-900
Abstract: © 2015 Elsevier Inc. The management of hepatitis C virus (HCV) infection in special populations is challenging. The efficacy and safety data of the currently approved all-oral direct-acting antiviral combinations, including sofosbuvir, ledipasvir, daclatasvir, paritaprevir/ritonavir/ombitasvir plus dasabuvir (3D), and ribavirin, is compelling for use in special HCV populations, as has recently been recommended by expert guidelines. The treatment regimens and sustained virological response rates for special populations are nearly similar to those of the general HCV population. Sofosbuvir is not recommended in patients with severe renal impairment, and simeprevir and 3D regimen are not recommended for those with decompensated liver disease.
ISSN: 15581942
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.